Jounce Therapeutics

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

At Jounce Therapeutics, our mission is to discover and develop innovative therapies that have the potential to transform outcomes for cancer patients.

Our vision is to become the premier source of transformational immunotherapies to treat cancer.

Jounce Therapeutics has been recognized with numerous awards, including being named one of the 2019 FierceBiotech Fierce 15 Biotech Companies, as well as “Startup of the Year” by MassBio and by MassTLC.